Phreesia (PHR) Expected to Announce Earnings on Monday

Phreesia (NYSE:PHR) is projected to post its Q3 2026 results after the market closes on Monday, December 8th. Analysts expect Phreesia to post earnings of ($0.01) per share and revenue of $119.98 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Monday, December 8, 2025 at 5:00 PM ET.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The business had revenue of $117.26 million for the quarter, compared to analysts’ expectations of $116.39 million. During the same period in the prior year, the company posted ($0.03) EPS. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Stock Down 1.4%

Shares of NYSE PHR opened at $20.26 on Friday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -48.24 and a beta of 0.64. Phreesia has a 52 week low of $18.55 and a 52 week high of $32.76. The firm has a 50-day moving average price of $22.09 and a 200 day moving average price of $25.27. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02.

Insider Buying and Selling at Phreesia

In other Phreesia news, insider David Linetsky sold 2,059 shares of the firm’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $22.36, for a total transaction of $46,039.24. Following the sale, the insider directly owned 171,829 shares of the company’s stock, valued at $3,842,096.44. This trade represents a 1.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Amy Beth Vanduyn sold 1,762 shares of Phreesia stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $41,019.36. Following the sale, the senior vice president owned 112,479 shares of the company’s stock, valued at approximately $2,618,511.12. This trade represents a 1.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 26,174 shares of company stock valued at $603,835. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC boosted its stake in shares of Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock valued at $4,090,000 after purchasing an additional 132,015 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after buying an additional 16,309 shares during the last quarter. Sherbrooke Park Advisers LLC lifted its holdings in Phreesia by 18.0% in the third quarter. Sherbrooke Park Advisers LLC now owns 20,425 shares of the company’s stock valued at $480,000 after buying an additional 3,119 shares during the period. Alliancebernstein L.P. boosted its stake in Phreesia by 1.3% in the third quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock valued at $1,475,000 after acquiring an additional 812 shares during the last quarter. Finally, Zacks Investment Management grew its holdings in Phreesia by 8.0% during the 3rd quarter. Zacks Investment Management now owns 58,915 shares of the company’s stock worth $1,386,000 after acquiring an additional 4,348 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PHR has been the subject of a number of research reports. JMP Securities lifted their price target on shares of Phreesia from $30.00 to $34.00 and gave the company a “market outperform” rating in a research report on Monday, September 8th. Stephens reaffirmed an “overweight” rating and set a $32.00 price objective on shares of Phreesia in a report on Wednesday, September 3rd. Citigroup reissued an “outperform” rating on shares of Phreesia in a report on Monday, September 8th. Canaccord Genuity Group raised their price target on Phreesia from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, September 5th. Finally, BMO Capital Markets began coverage on shares of Phreesia in a research report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price objective on the stock. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.86.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.